Ticker League

Bristol-Myers Squibb (BMY) Free Cash Flow Bridge

Pinpoint what moved Bristol-Myers Squibb's free cash flow from TTM through Q1 2025 to TTM through Q1 2026 — operating cash flow shifts and capex changes, each driver sized in dollars.

FCF YoY

-9.00%

OCF YoY

-7.02%

Capex YoY

+14.22%

FCF Conversion Δ

-2 pp

Free cash flow bridge for Bristol-Myers Squibb (BMY) — TTM through Q1 2026 vs TTM through Q1 2025

Δ Free cash flow: −$1.18B

FCF bridge breakdown for Bristol-Myers Squibb (BMY) — TTM through Q1 2026 vs TTM through Q1 2025

  • Prior Free Cash Flow$13.09B
  • Operating Cash Flow−$1.00B
  • Capital Expenditure−$174.00M
  • Free Cash Flow$11.91B
Identity check: drivers reconcile to ΔNI within $0.00
Want to see how cash flow is built up?Cash Flow Waterfall

Frequently asked questions

Data & methodology